mRNA |
brivanib |
CTRPv2 |
pan-cancer |
AAC |
-0.023 |
0.5 |
mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
-0.023 |
0.5 |
mRNA |
SNX-2112:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.021 |
0.5 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.022 |
0.5 |
mRNA |
NVP-ADW742 |
CTRPv2 |
pan-cancer |
AAC |
0.022 |
0.5 |
mRNA |
SR8278 |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.5 |
mRNA |
BYL-719 |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.5 |
mRNA |
16-beta-bromoandrosterone |
CTRPv2 |
pan-cancer |
AAC |
0.024 |
0.5 |
mRNA |
Bortezomib |
gCSI |
pan-cancer |
AAC |
-0.039 |
0.5 |
mRNA |
linifanib |
CTRPv2 |
pan-cancer |
AAC |
-0.023 |
0.5 |